Cullinan Therapeutics to Showcase New Multi-Dose Clinical Data for Autoimmune Drugs CLN-978 and Velinotamig on June 10
CGEM has more than doubled off its 52-week low of $5.68.
Summary
Cullinan Therapeutics will host an Immunology Day on June 10th to present new and updated clinical data for its autoimmune drug candidates, CLN-978 and velinotamig. The event will feature initial multi-dose cohort data for CLN-978 in rheumatoid arthritis and initial multi-dose cohort data for velinotamig in autoimmune diseases. This builds on the positive initial Phase 1 data for CLN-978 announced on May 18th, now adding multi-dose results and initial data for velinotamig. The company's Q1 2026 10-Q on May 7th highlighted a 12-month cash runway, making pipeline progress crucial. Presenting multi-dose data is a key advancement in clinical development, potentially validating the company's T cell engager platform and supporting its long-term strategy and financing needs. The full data presentation at the Immunology Day event on June 10th will be closely watched.
At the time of this announcement, CGEM was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $850.6M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.